{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T04:49:32Z","timestamp":1775278172038,"version":"3.50.1"},"reference-count":35,"publisher":"Japanese Society of Internal Medicine","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026,4,1]]},"DOI":"10.2169\/internalmedicine.5954-25","type":"journal-article","created":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T22:07:15Z","timestamp":1756937235000},"page":"966-972","source":"Crossref","is-referenced-by-count":0,"title":["Clinical Characteristics and Outcomes of Patients with a Positive Finding for the Coronary Spasm Provocation Test at Low Acetylcholine Doses"],"prefix":"10.2169","volume":"65","author":[{"given":"Hiroki","family":"Kuji","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Chiba University Graduate School of Medicine, Japan"},{"name":"Division of Cardiology, Chiba Cerebral and Cardiovascular Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichi","family":"Saito","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Chiba University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shota","family":"Kuranaga","sequence":"additional","affiliation":[{"name":"Clinical Resident, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Nishi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Chiba University Graduate School of Medicine, Japan"},{"name":"Department of Internal Medicine, Division of Cardiology, NewYork-Presbyterian Brooklyn Methodist Hospital, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuya","family":"Tateishi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Chiba University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Chiba University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Kitahara","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Chiba University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshio","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Chiba University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Hokimoto S, Kaikita K, Yasuda S, et al.; Japanese Circulation Society and Japanese Association of Cardiovascular Intervention and Therapeutics and Japanese College of Cardiology Joint Working Group. JCS\/CVIT\/JCC 2023 Guideline Focused Update on Diagnosis and Treatment of Vasospastic Angina (Coronary Spastic Angina) and Coronary Microvascular Dysfunction. Circ J 87: 879-936, 2023.","DOI":"10.1253\/circj.CJ-22-0779"},{"key":"2","unstructured":"2. Vrints C, Andreotti F, Koskinas KC, et al.; ESC Scientific Document Group. 2024 ESC Guidelines for the management of chronic coronary syndromes. Eur Heart J 45: 3415-3537, 2024."},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Ford TJ, Stanley B, Good R, et al. Stratified medical therapy using invasive coronary function testing in angina: the CorMicA trial. J Am Coll Cardiol 72: 2841-2855, 2018.","DOI":"10.1016\/j.jacc.2018.09.006"},{"key":"4","unstructured":"4. Takagi Y, Takahashi J, Yasuda S, et al.; Japanese Coronary Spasm Association. Prognostic stratification of patients with vasospastic angina: a comprehensive clinical risk score developed by the Japanese Coronary Spasm Association. J Am Coll Cardiol 62: 1144-1153, 2013."},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Takahashi T, Samuels BA, Li W, et al.; Microvascular Network. Safety of provocative testing with intracoronary acetylcholine and implications for standard protocols. J Am Coll Cardiol 79: 2367-2378, 2022.","DOI":"10.1016\/j.jacc.2022.03.385"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Rehan R, Beltrame J, Yong A. Insights into the invasive diagnostic challenges of coronary artery vasospasm - a systematic review. J Cardiol 83: 8-16, 2024.","DOI":"10.1016\/j.jjcc.2023.07.020"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Saito Y, Kitahara H, Shoji T, et al. Intracoronary acetylcholine provocation testing - omission of the 20-\u03bcg dose is feasible in patients without coronary artery spasm in the other coronary artery. Circ J 80: 1820-1823, 2016.","DOI":"10.1253\/circj.CJ-16-0344"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Saito Y, Kitahara H, Shoji T, et al. Paroxysmal atrial fibrillation during intracoronary acetylcholine provocation test. Heart Vessels 32: 902-908, 2017.","DOI":"10.1007\/s00380-016-0939-2"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Saito Y, Kitahara H, Nishi T, Fujimoto Y, Kobayashi Y. Decreased resting coronary flow and impaired endothelial function in patients with vasospastic angina. Coron Artery Dis 30: 291-296, 2019.","DOI":"10.1097\/MCA.0000000000000721"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Saito Y, Kitahara H, Shoji T, Nakayama T, Fujimoto Y, Kobayashi Y. Decreased double product at rest in patients with severe vasospasm. Heart Lung Circ 29: 1511-1516, 2020.","DOI":"10.1016\/j.hlc.2020.02.007"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Sueda S, Kohno H. Transitional changes of acetylcholine spasm provocation test procedures. Cardiovasc Interv Ther 35: 321-326, 2020.","DOI":"10.1007\/s12928-019-00624-7"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Suzuki S, Kaikita K, Yamamoto E, Jinnouchi H, Tsujita K. Role of acetylcholine spasm provocation test as a pathophysiological assessment in nonobstructive coronary artery disease. Cardiovasc Interv Ther 36: 39-51, 2021.","DOI":"10.1007\/s12928-020-00720-z"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Ando H, Yamaji K, Kohsaka S, et al.; J-PCI Registry Investigators. Japanese Nationwide PCI (J-PCI) Registry Annual Report 2019: patient demographics and in-hospital outcomes. Cardiovasc Interv Ther 37: 243-247, 2022.","DOI":"10.1007\/s12928-021-00832-0"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Fujii T, Amano K, Kasai S, Kawamura Y, Yoshimachi F, Ikari Y. Impact of renal function on adverse bleeding events associated with dual antiplatelet therapy in patients with acute coronary syndrome. Cardiovasc Interv Ther 39: 28-33, 2024.","DOI":"10.1007\/s12928-023-00963-6"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Nakanishi N, Kaikita K, Ishii M, et al. Japanese high bleeding risk criteria status predicts low thrombogenicity and bleeding events in patients undergoing percutaneous coronary intervention. Cardiovasc Interv Ther 38: 299-308, 2023.","DOI":"10.1007\/s12928-023-00920-3"},{"key":"16","doi-asserted-by":"publisher","unstructured":"16. Hicks KA, Mahaffey KW, Mehran R, et al.; Standardized Data Collection for Cardiovascular Trials Initiative (SCTI). 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. Circulation 137: 961-972, 2018.","DOI":"10.1161\/CIRCULATIONAHA.117.033502"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Huang J, Steinberg R, Brown MJ, Rinfret S, Toleva O. Invasive evaluation for coronary vasospasm. US Cardiol 17: e07, 2023.","DOI":"10.15420\/usc.2022.33"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Ludmer PL, Selwyn AP, Shook TL, et al. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med 315: 1046-1051, 1986.","DOI":"10.1056\/NEJM198610233151702"},{"key":"19","doi-asserted-by":"publisher","unstructured":"19. Yaker ZS, Lincoff AM, Cho L, et al. Coronary spasm and vasomotor dysfunction as a cause of MINOCA. EuroIntervention 20: e123-e134, 2024.","DOI":"10.4244\/EIJ-D-23-00448"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Sueda S, Kohno H, Fukuda H, et al. Clinical and angiographical characteristics of acetylcholine-induced spasm: relationship to dose of intracoronary injection of acetylcholine. Coron Artery Dis 13: 231-236, 2002.","DOI":"10.1097\/00019501-200206000-00005"},{"key":"21","doi-asserted-by":"publisher","unstructured":"21. Im SI, Rha SW, Choi BG, et al. Angiographic and clinical characteristics according to intracoronary acetylcholine dose in patients with myocardial bridge. Cardiology 125: 250-257, 2013.","DOI":"10.1159\/000351181"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Im SI, Choi WG, Rha SW, et al. Significant response to lower acetylcholine dose is associated with worse clinical and angiographic characteristics in patients with vasospastic angina. Korean Circ J 43: 468-473, 2013.","DOI":"10.4070\/kcj.2013.43.7.468"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Saito Y, Saito Y, Kato K, Kobayashi Y. Gender differences in factors associated with vasospastic angina. Int J Cardiol 349: 7-11, 2022.","DOI":"10.1016\/j.ijcard.2021.11.047"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Tateishi K, Saito Y, Kitahara H, et al. Safety and usefulness of acetylcholine provocation test in patients with no culprit lesions on emergency coronary angiography. Int J Cardiol 269: 27-30, 2018.","DOI":"10.1016\/j.ijcard.2018.06.108"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Saito Y, Kobayashi Y, Tsujita K, et al. Pharmacological and device-based intervention for preventing heart failure after acute myocardial infarction - a clinical review. Circ J 88: 1727-1736, 2024.","DOI":"10.1253\/circj.CJ-24-0633"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Kurobe M, Baba K, Nunohiro T, et al. Impact of implementation of a region-wide low-density lipoprotein cholesterol management clinical pathway for the secondary prevention of acute myocardial infarction. Circ J 88: 1825-1832, 2024.","DOI":"10.1253\/circj.CJ-24-0338"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Yamamoto K, Yamamoto E, Morimoto T, et al. Long-term effects of proton pump inhibitors in patients undergoing percutaneous coronary intervention in high-risk subgroups. Circ J 88: 1778-1787, 2024.","DOI":"10.1253\/circj.CJ-24-0371"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Isogai T, Michihata N, Okada A, et al. Use of Japanese herbal kampo medicine in patients with acute cardiovascular disease - a 12-year nationwide cohort analysis. Circ J 88: 1322-1331, 2024.","DOI":"10.1253\/circj.CJ-23-0770"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Suzuki Y, Kaneko H, Okada A, et al. Awareness of being prescribed antihypertensive medications and cardiovascular outcomes. Circ J 88: 1639-1646, 2024.","DOI":"10.1253\/circj.CJ-24-0039"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Ishida M, Shimada R, Takahashi F, et al.; REIWA Investigators. One-month dual antiplatelet therapy followed by P2Y<sub>12<\/sub> inhibitor monotherapy after biodegradable polymer drug-eluting stent implantation - the REIWA region-wide registry. Circ J 88: 876-884, 2024.","DOI":"10.1253\/circj.CJ-24-0091"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Sheng F, Wang AY, Miyawaki K, et al. Real-world clinical profile of patients prescribed evolocumab in Japan. Circ J 88: 1629-1636, 2024.","DOI":"10.1253\/circj.CJ-23-0814"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Nishihira K, Nakai M, Kuriyama N, et al. Guideline-directed medical therapy for elderly patients with acute myocardial infarction who undergo percutaneous coronary intervention - insights from a retrospective observational study. Circ J 88: 931-937, 2024.","DOI":"10.1253\/circj.CJ-23-0837"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Yamamoto K, Morimoto T, Natsuaki M, et al.; CREDO-Kyoto PC1\/CABG Registry Cohort-3 Investigators. Polypharmacy and bleeding outcomes after percutaneous coronary intervention. Circ J 88: 888-899, 2024.","DOI":"10.1253\/circj.CJ-23-0558"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Yamamoto K, Shiomi H, Morimoto T, et al.; OPTIVUS-Complex PCI Investigators. Dual antiplatelet therapy duration after multivessel optimal intravascular ultrasound-guided percutaneous coronary intervention. Circ J 87: 1661-1671, 2023.","DOI":"10.1253\/circj.CJ-23-0141"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Sawayama Y, Tomita Y, Kohyama S, et al. Clopidogrel use in <i>CYP2C19<\/i> loss-of-function carriers with high bleeding risk after percutaneous coronary intervention. Circ J 87: 755-763, 2023.","DOI":"10.1253\/circj.CJ-22-0826"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/7\/65_5954-25\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T03:55:15Z","timestamp":1775274915000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/7\/65_5954-25\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":35,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.5954-25","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,1]]},"article-number":"5954-25"}}